Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients
Autor
Zheng, Meijuan
Gao, Yong
Liu, Siyu
Sun, Dandan
Yang, Fan
Zong, Lu
Zhang, Min
Tian, Zhigang
Xu, Yuanhong
Sun, Haoyu
Institución
Resumen
The ongoing spread of coronavirus disease 2019 (COVID-19)
constitutes an international concern on an unprecedented scale.
To date, over 23 million people have been diagnosed with COVID19 worldwide, and this disease has caused more than 800,000
deaths. Hyperinflammation elicited by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has been reported to
contribute to illness severity and death.1,2 Humoral immune
responses play important roles in therapy and prophylaxis for
SARS-CoV-2 infection. Since the receptor-binding domain (RBD)
of the SARS-CoV-2 spike (S) glycoprotein binds to angiotensinconverting enzyme 2 to trigger virion endocytosis, antibodies
against this domain may be able to neutralize SARS-CoV-2 and
possibly provide protective immunity in COVID-19 patients.3
Clinical trials investigating the administration of convalescent
plasma and the interleukin (IL)-6 antagonist tocilizumab to treat
COVID-19 patients are currently underway,4 but the overly robust
expansion of antibody-secreting cells (ASCs) could play a major
role in the pathogenicity of SARS-CoV-2 in COVID-19 patients.5
Thus, a detailed characterization of the associations between
humoral immune responses and inflammatory factors could result
in a better understanding of SARS-CoV-2-host interactions in
COVID-19 patients.